Table 1 AChEI agents approved by the FDA: prescription share and prescription volume
From: Current pharmacologic options for patients with Alzheimer's disease
Agent for AD Treatment | Prescription Share | Prescription Volume |
|---|---|---|
Tacrine | < 1% | – |
Donepezil | ~66% | ~530,000 |
Rivastigmine | ~20% | ~160,000 |
Galantamine | ~14% | ~110,000 |